Grant of Interim Extension of the Term of U.S. Patent No. 5,593,823; INTERCEPT® Blood System for Plasma, 491-492 [2014-30945]
Download as PDF
Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
Matters To Be Considered: The
Committee will receive reports on the
progress of the following subcommittees
established to help NTIA develop new
or revised strategies for responding
more efficiently and effectively to
fundamental technological, operational,
and other trends to continue
advancement of delivering spectrum
products, services, and solutions that
will support the ever-increasing demand
for spectrum:
1. Enforcement
2. Transitional Sharing
3. General Occupancy Measurements
and Quantification of Federal
Spectrum Use
4. Spectrum Management via Databases
5. Federal Access to Non-federal Bands
(Bi-Directional Sharing)
6. Spectrum Sharing Cost Recovery
Alternatives
7. Industry and Government
Collaboration
NTIA will post a detailed agenda on
its Web site, https://www.ntia.doc.gov/
category/csmac, prior to the meeting. To
the extent that the meeting time and
agenda permit, any member of the
public may speak to or otherwise
address the Committee regarding the
agenda items. See Open Meeting and
Public Participation Policy, available at
https://www.ntia.doc.gov/category/
csmac.
Time and Date: The meeting will be
held on February 18, 2015, from 1:00
p.m. to 4:00 p.m., Eastern Standard
Time. The times and the agenda topics
are subject to change. The meeting will
be available via two-way audio link and
may be webcast. Please refer to NTIA’s
Web site, https://www.ntia.doc.gov/
category/csmac, for the most up-to-date
meeting agenda and access information.
Place: The meeting will be held at the
Raytheon Company, 1100 Wilson
Boulevard, 20th Floor, Rosslyn, VA
22209–2249. Public comments may be
mailed to Commerce Spectrum
Management Advisory Committee,
National Telecommunications and
Information Administration, 1401
Constitution Avenue NW., Room 4099,
Washington, DC 20230. The meeting
will be open to the public and press on
a first-come, first-served basis. Space is
limited. All visitors, especially Foreign
National Visitors, must send a written
request to participate in the meeting on
site. Visit request must be provided to
Mr. Washington at BWashington@
ntia.doc.gov no later than February 6,
2015. The public meeting is physically
accessible to people with disabilities.
Individuals requiring accommodations,
such as sign language interpretation or
other ancillary aids, are asked to notify
VerDate Sep<11>2014
19:38 Jan 05, 2015
Jkt 235001
Mr. Washington at (202) 482–6415 or
BWashington@ntia.doc.gov at least ten
(10) business days before the meeting.
Status: Interested parties are invited
to attend and to submit written
comments to the Committee at any time
before or after the meeting. Parties
wishing to submit written comments for
consideration by the Committee in
advance of a meeting must send them to
NTIA’s Washington, DC office at the
above-listed address and comments
must be received five (5) business days
before the scheduled meeting date, to
provide sufficient time for review.
Comments received after this date will
be distributed to the Committee, but
may not be reviewed prior to the
meeting. It would be helpful if paper
submissions also include a compact disc
(CD) in Word or PDF format. CDs should
be labeled with the name and
organizational affiliation of the filer.
Alternatively, comments may be
submitted electronically to
BWashington@ntia.doc.gov. Comments
provided via electronic mail also may be
submitted in one or more of the formats
specified above.
Records: NTIA maintains records of
all Committee proceedings. Committee
records are available for public
inspection at NTIA’s Washington, DC
office at the address above. Documents
including the Committee’s charter,
member list, agendas, minutes, and any
reports are available on NTIA’s
Committee Web page at https://
www.ntia.doc.gov/category/csmac.
Dated: December 30, 2014.
Kathy D. Smith,
Chief Counsel, National Telecommunications
and Information Administration.
[FR Doc. 2014–30872 Filed 1–5–15; 8:45 am]
BILLING CODE 3510–60–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No.: PTO–P–2014–0068]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,593,823;
INTERCEPT® Blood System for Plasma
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a second interim extension
under 35 U.S.C. 156(d)(5) for a one-year
interim extension of the term of U.S.
Patent No. 5,593,823.
SUMMARY:
PO 00000
Frm 00011
Fmt 4703
Sfmt 4703
491
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755; or by email to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On December 5, 2014, Cerus
Corporation, the patent owner of record,
timely filed an application under 35
U.S.C. 156(d)(5) for a second interim
extension of the term of U.S. Patent No.
5,593,823. The patent claims the
medical device INTERCEPT® Blood
System for Plasma. The application
indicates that a Premarket Approval
Application (PMA) was submitted to the
Food and Drug Administration (FDA) in
four modules. The PMA Shell number
BM120078 was assigned on December 5,
2012. The first module was received by
the FDA on March 1, 2013, the second
module was received on June 3, 2013,
by the FDA, the third module was
received by the FDA on September 3,
2013, and the fourth module was
received by the FDA on November 29,
2013. The medical device is currently
undergoing regulatory review before the
FDA for permission to market or use the
product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the
extended expiration date of the patent,
January 14, 2015, interim extension of
the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,593,823 is granted for a period of one
year from the extended expiration date
of the patent.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\06JAN1.SGM
06JAN1
492
Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices
Dated: December 23, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination
Policy United States Patent and Trademark
Office.
[FR Doc. 2014–30945 Filed 1–5–15; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Agency Information Collection
Activities Under OMB Review
Commodity Futures Trading
Commission.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995
(PRA), this notice announces that the
Information Collection Request (ICR)
abstracted below has been forwarded to
the Office of Management and Budget
(OMB) for review and comment. The
ICR describes the nature of the
information collection and its expected
costs and burden.
DATES: Comments must be submitted on
or before February 5, 2014.
ADDRESSES: Comments may be
submitted directly to the Office of
Information and Regulatory Affairs
(OIRA) in OMB, within 30 days of the
notice’s publication, by email at
OIRAsubmissions@omb.eop.gov. Please
identify comments by ‘‘Financial
Resource Reporting Requirements for
Derivatives Clearing Organizations
(OMB Control No. 3038–0066).’’ Please
provide the Commission with a copy of
all submitted comments at the address
listed below. Comments may also be
mailed to the Office of Information and
Regulatory Affairs, Office of
Management and Budget, Attention:
Desk Officer for the Commodity Futures
Trading Commission, 725 17th Street
NW., Washington, DC 20503, and Eileen
Chotiner, Division of Clearing and Risk,
Commodity Futures Trading
Commission, Three Lafayette Centre,
1155 21st Street NW., Washington, DC
20581.
Comments may be also be submitted,
regarding the burden estimated or any
other aspect of the information
collection, including suggestions for
reducing the burden, identified by
‘‘Financial Resource Requirements for
Derivatives Clearing Organizations
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:38 Jan 05, 2015
Jkt 235001
(OMB Control No. 3038–0066),’’ by any
of the following methods:
• Agency Web site, via its Comments
Online process: https://
comments.cftc.gov. Follow the
instructions for submitting comments
through the Web site.
• Mail: Send to Christopher
Kirkpatrick, Secretary of the
Commission, Commodity Futures
Trading Commission, Three Lafayette
Centre, 1155 21st Street NW.,
Washington, DC 20581.
• Hand Delivery/Courier: Same as
Mail, above.
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
All comments must be submitted in
English or, if not, accompanied by an
English translation. Comments will be
posted as received to https://
www.cftc.gov. You should submit only
information that you wish to make
available publicly. If you wish the
Commission to consider information
that is exempt from disclosure under the
Freedom of Information Act, a petition
for confidential treatment of the exempt
information may be submitted according
to the procedures set forth in § 145.9 of
the Commission’s regulations.
The Commission reserves the right,
but shall have no obligation, to review,
pre-screen, filter, redact, refuse or
remove any or all of your submission
from www.cftc.gov that it may deem to
be inappropriate for publication, such as
obscene language. All submissions that
have been redacted or removed that
contain comments on the merits of this
matter will be retained in the public
comment file and will be considered as
required under applicable laws.
FOR FURTHER INFORMATION CONTACT:
Eileen Chotiner, Division of Clearing
and Risk, Commodity Futures Trading
Commission, Three Lafayette Centre,
1155 21st Street NW., Washington, DC
20581; (202) 418–5467; email:
echotiner@cftc.gov, and refer to OMB
Control number 3038–0066. This
contact can also provide a copy of the
ICR.
SUPPLEMENTARY INFORMATION: This is a
request for extension of a currently
approved information collection.
Title: ‘‘Financial Resource Reporting
Requirements for Derivatives Clearing
Organizations (OMB Control No. 3038–
0066).’’
PO 00000
Frm 00012
Fmt 4703
Sfmt 4703
Abstract: Part 39 of the Commission’s
regulations establishes financial
reporting requirements for derivatives
clearing organizations (DCOs), which
are required to be registered with the
Commission. The Commission will use
the information in the reports to assess
the DCOs’ compliance with the financial
resource requirements for DCOs
prescribed in the Commodity Exchange
Act and Commission regulations.
Burden Statement: The respondent
burden for this collection is estimated to
average 10 hours per response.
Respondents/Affected Entities:
Derivatives clearing organizations.
Estimated Number of Respondents:
14.
Estimated Total Annual Burden on
Respondents: 560 hours.
Frequency of Collection: Quarterly
and on occasion.
Authority: 44 U.S.C. 3501 et seq.
Dated: December 31, 2014.
Christopher J. Kirkpatrick,
Secretary of the Commission.
[FR Doc. 2014–30950 Filed 1–5–15; 8:45 am]
BILLING CODE 6351–01–P
DEPARTMENT OF DEFENSE
Office of the Secretary
[Transmittal Nos. 13–45]
36(b)(1) Arms Sales Notification
Defense Security Cooperation
Agency, Department of Defense.
ACTION: Notice.
AGENCY:
The Department of Defense is
publishing the unclassified text of a
section 36(b)(1) arms sales notification.
This is published to fulfill the
requirements of section 155 of Public
Law 104–164 dated July 21, 1996.
FOR FURTHER INFORMATION CONTACT: Ms.
B. English, DSCA/DBO/CFM, (703) 601–
3740.
The following is a copy of a letter to
the Speaker of the House of
Representatives, Transmittals 13–45
with attached transmittal, policy
justification, and Sensitivity of
Technology.
SUMMARY:
Dated: December 31, 2014.
Aaron Siegel,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
E:\FR\FM\06JAN1.SGM
06JAN1
Agencies
[Federal Register Volume 80, Number 3 (Tuesday, January 6, 2015)]
[Notices]
[Pages 491-492]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-30945]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No.: PTO-P-2014-0068]
Grant of Interim Extension of the Term of U.S. Patent No.
5,593,823; INTERCEPT[supreg] Blood System for Plasma
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a second interim extension under 35 U.S.C. 156(d)(5) for
a one-year interim extension of the term of U.S. Patent No. 5,593,823.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On December 5, 2014, Cerus Corporation, the patent owner of record,
timely filed an application under 35 U.S.C. 156(d)(5) for a second
interim extension of the term of U.S. Patent No. 5,593,823. The patent
claims the medical device INTERCEPT[supreg] Blood System for Plasma.
The application indicates that a Premarket Approval Application (PMA)
was submitted to the Food and Drug Administration (FDA) in four
modules. The PMA Shell number BM120078 was assigned on December 5,
2012. The first module was received by the FDA on March 1, 2013, the
second module was received on June 3, 2013, by the FDA, the third
module was received by the FDA on September 3, 2013, and the fourth
module was received by the FDA on November 29, 2013. The medical device
is currently undergoing regulatory review before the FDA for permission
to market or use the product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review
period will continue beyond the extended expiration date of the patent,
January 14, 2015, interim extension of the patent term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,593,823 is granted for a period of one year from the
extended expiration date of the patent.
[[Page 492]]
Dated: December 23, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy United States Patent
and Trademark Office.
[FR Doc. 2014-30945 Filed 1-5-15; 8:45 am]
BILLING CODE 3510-16-P